In opioid addiction disease area, we are the only company with differentiated versions of each of the three molecules used to manage this important health problem. Our products provide clinically proven interventions for all stages of treatment and support:
Reducing drug-related deaths, we developed and launched Prenoxad Injection, the world’s first licensed presentation of naloxone specifically for use in a community/non clinical setting by a non-healthcare professional to reverse opioid overdose. This is saving lives every day in the UK and we plan to be approved and launched in a number of European markets during 2016.
Visit www.prenoxadinjection.com for further information.
Stopping the use of illegal opioids – we believe our Physeptone brand of methadone oral solution in the UK and our international methadone oral solution products represent the most comprehensive range of methadone products for opioid substitution therapy. They have been formulated to meet multiple patient, pharmacist and prescriber needs.
We have developed and obtained first EU regulatory approvals for Espranor, a buprenorphine oral wafer, which disintegrates instantly when placed on the tongue and offers improved patient and prescriber acceptability compared to current buprenorphine products. Espranor has the potential to transform the opioid substitution market and can play a key role in helping patients in treatment move towards recovery.